Sep 25, 2019
Theravance Biopharma to Present at the 2019 Cantor Global Healthcare Conference
Sep 17, 2019
U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Sep 17, 2019
REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor
Aug 28, 2019
Theravance Biopharma to Present at Two Upcoming Investor Conferences
Aug 09, 2019
U.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit
Jul 31, 2019
Theravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
Jul 11, 2019
NCCN issues first pediatric acute lymphoblastic leukemia guidelines, including use of Voraxaze®
Jun 14, 2019
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories
Jun 04, 2019
Theravance Biopharma Appoints Andrew Hindman as Senior Vice President and Chief Financial Officer
May 31, 2019
ERLEADA® (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
May 28, 2019
Sierra Oncology to Present Momelotinib and SRA737 Overview at the Jefferies Global Healthcare Conference in New York
May 20, 2019
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference
May 08, 2019
AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience
May 07, 2019
Theravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
May 07, 2019
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019
May 06, 2019
Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update
May 04, 2019
Preclinical Data Highlighting Therapeutic Potential of EPI-7386 Presented at 2019 American Urological Association Annual Meeting
Apr 02, 2019
Theravance Biopharma to Present at the 18th Annual Needham Healthcare Conference
Mar 20, 2019
Xynomic Pharmaceuticals, Inc. Will Present at ASCO 2019 Annual Meeting, Will Sponsor an EU Investigator Meeting for Potentially Pivotal Kidney Cancer Trial, and Appoints Interim Chief Accounting Officer
Mar 07, 2019
Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update